OncLive TV

Joleen M. Hubbard, MD, discusses minimal residual disease assessment to inform treatment decisions in patients with resected metastatic colorectal cancer.

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.

Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

Bhagirathbhai Dholaria, MBBS, discusses patient characteristics in the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Janakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer. 

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer. 

Edgardo S. Santos, MD, FACP, discusses the importance of identifying mechanisms of resistance in lung cancer.

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.

Nicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.

Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

Luis E. Raez, MD, discusses the clinical implications of the phase 3 KEYNOTE-024 trial in non–small cell lung cancer.

Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

Maria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.

Julio Aguirre-Ghiso, PhD, discusses future research directions being conducted by investigators at the Albert Einstein Cancer Center.

Miranda Gogishvili, MD, discusses the rationale for the phase 3 EMPOWER-Lung 3 trial in advanced or metastatic non–small cell lung cancer.

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Rachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.